Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass

Influence of Cardiopulmonary Bypass on Platelet Function in Patients With Preoperative Dual Antiplatelet Therapy:

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02979158

Enrollment

Registered

2016-12-01

Start date

2016-11-30

Completion date

2018-01-24

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding Disorder, Cardiopulmonary Bypass, Platelet Disorder, Platelet Dysfunction Due to Drugs

Brief summary

Patients admitted for coronary artery bypass surgery taking antiplatelet medicine have an increased risk for bleeding. Present study aims to compare the platelet function in two patient groups using different types of heart-lung machine methods. It is assumed that one of the methods is superior verified by sensitive methods of testing platelet function.

Detailed description

Taking antiplatelet medication before cardiac surgery increases the risk for bleeding. The surgical procedure and the use of a heart-lung machine may disturb the function of platelets, why measures to protect the existing function of platelets are of prime concern. The present study aims to compare how two types of heart-lung machine methods influence platelet function in two groups of patients. The platelet function will be tested before, during and after surgery by the use of two independent methods.

Interventions

PROCEDURECPB Low Dose

Performing CPB with low dose heparin and coated equipment

PROCEDURECPB High Dose

Performing CPB with high dose heparin and uncoated equipment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients accepted for coronary bypass surgery with dual preoperative antiplatelet therapy suspended less than 4 days prior to surgery

Exclusion criteria

* Abnormal coagulation verified from preoperative assessments, platelet count \<100 000, Warfarin medication and renal insufficiency (GFR \< 60 ml/min)

Design outcomes

Primary

Measure	Time frame	Description
Assessment of platelet function following cardiopulmonary bypass using platelet aggregometry	Test of platelet function will be analysed on arrival to the operating room, post cardiopulmonary bypass and on day 1 in the intensive care unit based on the area under the curve depited from the two employed aggremometers	Included aggregometry tests: Multiplate and Rotem Platelet

Secondary

Measure	Time frame	Description
Postoperative bleeding	Postoperative bleeding 24 hrs	Blood loss 24 hrs post surgery

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026